Edition:
United States

Astellas Pharma Inc (ALPMF.PK)

ALPMF.PK on OTC Markets Group

15.99USD
22 Jul 2016
Change (% chg)

$0.02 (+0.13%)
Prev Close
$15.97
Open
$15.99
Day's High
$15.99
Day's Low
$15.99
Volume
200
Avg. Vol
22,616
52-wk High
$16.50
52-wk Low
$12.50

Select another date:

Tue, Jun 7 2016

BRIEF-Xcelra enters into drug collaboration with Astellas Pharma

* Xcelra enters into a drug repurposing collaboration with Astellas Pharma

BRIEF-Medivation and Astellas initiate Phase III trial of enzalutamide

* Astellas and Medivation initiate Phase III trial of enzalutamide in patients with triple-negative breast cancer

BRIEF-Boya Bio-Pharmaceutical plans to invest 150 mln yuan to set up buyout fund with partners

* Says it plans to invest 150 million yuan ($22.99 million) to set up buyout fund in medical industry with partners

BRIEF-Astellas Pharma to retire 68 mln treasury shares

* Says it will retire 68 million shares (3.1 percent stake) of its common stock on June 20

BRIEF-Astellas to retire treasury stock equivalent to 3.06 pct of shares outstanding

* to retire treasury stock equivalent to 3.06 percent of shares outstanding on June 20 Further company coverage:

BRIEF-Astellas Pharma names Rodrigo Fernandez executive director, international business

* Astellas names Rodrigo Fernandez executive director, international business Source text for Eikon: Further company coverage:

UPDATE 1-U.S. lawmakers want health agencies to lower prostate cancer drug cost

March 28 A group of lawmakers is calling on the National Institutes of Health and Department of Health and Human Services to step in and reduce the cost of Medivation Inc's and Astellas Pharma Inc's prostate cancer drug Xtandi.

BRIEF-Astellas Pharma Inc initiates pivotal phase III trial of Enzalutamide

* Pivotal phase III trial of Enzalutamide initiated in Metastatic Hormone Sensitive Prostate Cancer Source text for Eikon: Further company coverage:

BRIEF-UK's CMA says not to refer Leo Pharma deal to buy Astellas Pharma portfolio to investigation

* Decided not to refer anticipated acquisition by Leo Pharma of the portfolio of pharma dermatological products of Astellas Pharma to phase 2 investigation Source text for Eikon: Further company coverage:

Select another date: